Impact News +++ Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of... (GlobeNewswire EN) +++ ASP ISOTOPES Aktie +4,38%

ALKERMES Aktie

>ALKERMES Aktienkurs

24.8 EUR -3.1% (Tradegate)

Ask: 26 EUR / 50 Stück

Bid: 25.2 EUR / 50 Stück

Tagesumsatz: 10 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ALKERMES Aktie über LYNX handeln

Intraday

1 Jahr

>ALKERMES Performance

1 Woche: -0,8%

1 Monat: +7,8%

3 Monate: -8,5%

6 Monate: -24,2%

1 Jahr: +2,5%

laufendes Jahr: -13,0%

>ALKERMES Aktie

Name:

ALKERMES PLC DL-,01

Land:

Irland

Sektor:

Gesundheit

ISIN/ Wkn:

IE00B56GVS15 / A1JKVH

Symbol/ Ticker:

8AK (Frankfurt) / ALKS (NASDAQ)

Kürzel:

FRA:8AK, ETR:8AK, 8AK:GR, NASDAQ:ALKS

Index:

Webseite:

https://www.alkermes.com/

Profil:

Alkermes plc is a prominent biopharmaceutical comp..
>Volltext..

Marktkapitalisierung:

4218.28 Mio. EUR

Unternehmenswert:

3422.41 Mio. EUR

Umsatz:

1284.74 Mio. EUR

EBITDA:

344.19 Mio. EUR

Nettogewinn:

297.39 Mio. EUR

Gewinn je Aktie:

1.82 EUR

Schulden:

62.03 Mio. EUR

Liquide Mittel:

444.83 Mio. EUR

Operativer Cashflow:

444.66 Mio. EUR

Bargeldquote:

2.01

Umsatzwachstum:

-9.23%

Gewinnwachstum:

9.74%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ALKERMES

Letzte Datenerhebung:

08.09.25

>ALKERMES Kennzahlen

Aktien/ Unternehmen:

Aktien: 165.08 Mio. St.

Frei handelbar: 97.36%

Leerverk. Aktien: 8.54%

Rückkaufquote: 1.43%

Mitarbeiter: 1800

Umsatz/Mitarb.: 0.74 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 39.25%

Bewertung:

KGV: 14.48

KGV lG: 18.17

KUV: 3.1

KBV: 3.06

PEG-Ratio: 0.57

EV/EBITDA: 9.94

Rentabilität:

Bruttomarge: 84.74%

Gewinnmarge: 23.12%

Operative Marge: 24.86%

Managementeffizenz:

Gesamtkaprendite: 15.61%

Eigenkaprendite: 23.94%

>ALKERMES Peer Group

Es sind 9 Aktien bekannt.

>ALKERMES Chart & Kurs - NASDAQ

>ALKERMES News

08.09.25 - 09:18	Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 (PR Newswire)
	– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor......

25.08.25 - 13:01	Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 (PR Newswire)
	– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00......

30.07.25 - 18:15	Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales (Zacks)
	ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues....

29.07.25 - 20:51	Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 16:45	Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
	The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....

29.07.25 - 16:00	Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates (Zacks)
	Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

29.07.25 - 15:01	Alkermes Q2 Sales Up 14 Percent (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 13:12	Alkermes GAAP EPS of $0.52 beats by $0.29, revenue of $390.7M beats by $49.4M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 13:01	Alkermes plc Reports Second Quarter 2025 Financial Results (PR Newswire)
	— Second Quarter Revenues of $390.7 Million — — GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — — Company Reiterates 2025 Financial Expectations — — Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025......

28.07.25 - 16:36	Alkermes Q2 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.07.25 - 17:30	Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
	Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

21.07.25 - 20:00	Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study (Benzinga)
	Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses. read more...

21.07.25 - 12:06	Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 (PR Newswire)
	– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to......

15.07.25 - 22:01	Alkermes to Report Second Quarter Financial Results on July 29, 2025 (PR Newswire)
	DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be......

15.07.25 - 21:33	Expert Outlook: Alkermes Through The Eyes Of 6 Analysts (Benzinga)
	Latest Ratings for ALKS DateFirmActionFromTo Jan 2022Cantor FitzgeraldUpgradesNeutralOverweight Dec 2021CitigroupInitiates Coverage OnNeutral Nov 2021SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for ALKS View the Latest Analyst Ratings read more...

14.07.25 - 17:30	How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% (Zacks)
	The consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

03.07.25 - 16:00	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
	EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty....

17.06.25 - 21:51	Alkermes upgraded at UBS on prospects for sleep disorder therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.06.25 - 14:06	Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) (Benzinga)
	Latest Ratings for ALKS DateFirmActionFromTo Jan 2022Cantor FitzgeraldUpgradesNeutralOverweight Dec 2021CitigroupInitiates Coverage OnNeutral Nov 2021SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for ALKS View the Latest Analyst Ratings read more...

11.06.25 - 01:02	Insiderhandel: SVP, Chief Commercial Officer verkauft Aktien von Alkermes im Wert von 103654 USD (Insiderkauf)
	Nichols, Christian Todd - Vorstand - Tag der Transaktion: 2025-06-10...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Mittelmaß . . . Die übliche Ballungszone des menschlichen Geistes. - Julio Cortázar

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram